Patents by Inventor Ludger Johannes
Ludger Johannes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240033366Abstract: Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.Type: ApplicationFiled: December 2, 2021Publication date: February 1, 2024Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT À L’ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), UNIVERSITE PARIS CITE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS)Inventors: Ludger JOHANNES, Anne BILLET, Jonathan ULMER, Denis SERVENT, Gilles MOURIER, Pascal KESSLER, Eric TARTOUR
-
Publication number: 20220233673Abstract: A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.Type: ApplicationFiled: June 4, 2020Publication date: July 28, 2022Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), COMMISSARIAT Á L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Anne BILLET, Frédéric SCHMIDT, Ludger JOHANNES, Denis SERVENT, Gilles MOURIER, Éric TARTOUR, Michael KAY, James M. FULCHER
-
Publication number: 20210107951Abstract: Disclosed are peptides, hosts expressing such peptides and a process for producing and screening such peptides or hosts. Also disclosed is use of the peptide or host expressing such peptide in the detection of disease, to a method for constructing a library of hosts, in particular of phages expressing peptides. Also disclosed is a library of hosts expressing peptides and its use for example for detecting molecules and/or cells in a sample, in the treatment of disease. These find application in the therapeutic and diagnostic medical technical fields.Type: ApplicationFiled: March 13, 2018Publication date: April 15, 2021Inventors: Thomas MURARASU, Franck PEREZ, Ludger JOHANNES
-
Patent number: 9603923Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.Type: GrantFiled: September 5, 2014Date of Patent: March 28, 2017Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI)Inventors: Ludger Johannes, Eric Tartour, Bruno Goud, Wolf Herve Fridman
-
Publication number: 20170042994Abstract: A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and/or a CpG-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases.Type: ApplicationFiled: July 29, 2016Publication date: February 16, 2017Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTESInventors: Eric TARTOUR, Ludger JOHANNES
-
Publication number: 20170015719Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B-X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.Type: ApplicationFiled: July 26, 2013Publication date: January 19, 2017Applicants: Inserm, Centre National de la Recherche Scientifique (CNRS), Institut Curie, Universite Pierre Et Marie Curie (Paris 6)Inventors: Bruno Goud, Ludger Johannes
-
Patent number: 9540356Abstract: The present invention concerns a new family of 2,3-dihydroquinazolin-4(1H)-one compounds of general formula (I), and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as ricin or Shiga toxin, for example, using retrograde transport to intoxicate cells.Type: GrantFiled: October 18, 2013Date of Patent: January 10, 2017Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Daniel Gillet, Julien Barbier, Ludger Johannes, Jean-Christophe Cintrat, Romain Noel
-
Publication number: 20150291568Abstract: The present invention concerns a new family of 2,3-dihydroquinazolin-4(1H)-one compounds of general formula (I), and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as ricin or Shiga toxin, for example, using retrograde transport to intoxicate cells.Type: ApplicationFiled: October 18, 2013Publication date: October 15, 2015Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Daniel Gillet, Julien Barbier, Ludger Johannes, Jean-Christophe Cintrat, Romain Noel
-
Patent number: 9034868Abstract: The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.Type: GrantFiled: November 19, 2013Date of Patent: May 19, 2015Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Daniel Gillet, Julien Barbier, Ludger Johannes, Bahne Stechmann, Siau-Kun Bai
-
Publication number: 20150045536Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.Type: ApplicationFiled: September 5, 2014Publication date: February 12, 2015Inventors: Ludger JOHANNES, Eric TARTOUR, Bruno GOUD, Wolf Herve FRIDMAN
-
Patent number: 8852612Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfhydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.Type: GrantFiled: September 29, 2009Date of Patent: October 7, 2014Assignees: Institute Curie, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Universite Pierre et Marie Curie (Paris VI)Inventors: Ludger Johannes, Eric Tartour, Bruno Goud, Wolf Herve Fridman
-
Publication number: 20140199379Abstract: A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and/or a CpG-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases.Type: ApplicationFiled: July 23, 2012Publication date: July 17, 2014Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Eric Tartour, Ludger Johannes
-
Publication number: 20140073633Abstract: The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.Type: ApplicationFiled: November 19, 2013Publication date: March 13, 2014Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIEInventors: Daniel GILLET, Julien BARBIER, Ludger JOHANNES, Bahne STECHMANN, Siau-Kun BAI
-
Patent number: 8609732Abstract: The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.Type: GrantFiled: June 17, 2009Date of Patent: December 17, 2013Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, Institut Curie, Centre National de la Recherche ScientfiqueInventors: Daniel Gillet, Julien Barbier, Ludger Johannes, Bahne Stechmann, Siau-Kun Bai
-
Patent number: 8524652Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B-X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.Type: GrantFiled: December 31, 2008Date of Patent: September 3, 2013Assignees: Inserm, Universite Pierre et Marie Curie (Paris 6), Institut Curie, Centre National de la Recherche Scientifique (CNRS)Inventors: Bruno Goud, Ludger Johannes
-
Patent number: 8313731Abstract: The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z(n) wherein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoid of sulfydryl group, or is a polypeptide, Cys is the amino-acid residue for Cysteine, T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.Type: GrantFiled: June 13, 2011Date of Patent: November 20, 2012Assignees: Institut Curie, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Universite Pierre et Marie Curie (Paris VI)Inventors: Ludger Johannes, David Grierson, Sylvie Robine, Jean-Claude Florent, Philipe Maillard, Jacky Roger
-
Publication number: 20110243914Abstract: The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z(n) whrein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoidof sulfydryl group, or is a polypeptide, Cys is the amino-acid residue for Cysteine, T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.Type: ApplicationFiled: June 13, 2011Publication date: October 6, 2011Inventors: Ludger JOHANNES, David Grierson, Sylvie Robine, Jean-Claude Florent, Philipe Maillard, Jacky Roger
-
Publication number: 20110201601Abstract: The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.Type: ApplicationFiled: June 17, 2009Publication date: August 18, 2011Applicants: COMMISSAR. A L'ENERG. ATOM. ET AUX ENERG. ALTERN., INSTITUT CURIE, CENTRE NAT DE LA RECHERCHE SCIENTIFIQUEInventors: Daniel Gillet, Julien Barbier, Ludger Johannes, Bahne Stechmann, Siau-Kun Bai
-
Patent number: 7981400Abstract: The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z(n) wherein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoid of sulfhydryl group, or is a polypeptide, Cys is the amino-acid residue for Cysteine, T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.Type: GrantFiled: March 12, 2010Date of Patent: July 19, 2011Assignees: Institut Curie, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Universite Pierre et Marie Curie (Paris VI)Inventors: Ludger Johannes, David Grierson, Sylvie Robine, Jean-Claude Florent, Philipe Maillard, Jacky Roger
-
Publication number: 20110152252Abstract: The present invention relates to the use of a Shiga toxin B-subunit moiety as carrier for therapeutic agents, for example, anti-cancer agents such as anti-cancer agents that require intracellular uptake to exert their anti-cancer effects. In particular, the present invention provides conjugates comprising a Shiga toxin moiety covalently linked to an anti-cancer agent through a self-immolative spacer, and methods of using such conjugates to increase cellular uptake and/or specificity for cancer cells of the anti-cancer drug. Also provided are methods of treatment involving administration of such conjugates, and pharmaceutical compositions and kits useful for carrying out such methods of treatment.Type: ApplicationFiled: December 18, 2007Publication date: June 23, 2011Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Ludger Johannes, Abdessamed El Alaoui, Didier Decaudin, Sylvie Robine, Frederic Schmidt, Jean-Claude Florent